Lacosamid Vivanta

Lacosamide, the active ingredient in Lacosamid Vivanta, is an anticonvulsant presented as an oral tablet for oral use. The product complies with EU quality standards and is manufactured under GMP conditions. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamid Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulatory‑approved documentation and supports global distribution through established logistics networks.

Lacosamide is used to control seizure activity within the focal seizure pathway of epilepsy.

- Partial‑onset seizures: reduces the frequency and severity of focal seizures in patients with epilepsy. - Focal seizures: provides adjunctive therapy to achieve better seizure control. - Epilepsy (overall): incorporated into broader treatment regimens to manage epilepsy when focal seizures are present.

Lacosamide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate pain in the head region. - Nausea: occasional upset stomach. - Fatigue: feeling unusually tired. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Cardiac arrhythmias: including PR‑interval prolongation. - Severe rash or hypersensitivity reactions: such as Stevens‑Johnson syndrome. - Suicidal thoughts or behavior: emergent mood changes requiring immediate evaluation. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe dizziness leading to falls. - Anaphylaxis: rare but life‑threatening allergic response.

When prescribing Lacosamid Vivanta, clinicians should consider several safety precautions.

- Renal impairment: adjust dose in patients with reduced renal function. - Hepatic impairment: monitor liver enzymes in patients with liver disease. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. - Pregnancy: safety unknown; weigh benefits against potential risks. - Driving and operating machinery: caution due to possible dizziness or visual disturbances. - Store at room temperature: keep in the original container, protect from moisture and light.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant use with other sodium‑channel blockers (e.g., carbamazepine, phenytoin) may increase risk of cardiac arrhythmias. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can lower lacosamide plasma concentrations. - Excessive alcohol intake: may enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: lacosamide may reduce effectiveness; consider alternative contraception. - Other antiepileptic drugs (e.g., valproate, levetiracetam): monitor seizure control and side‑effect profile. - Antidepressants (e.g., SSRIs): observe for additive dizziness or sedation.